Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group, Inc. director Robert Bessler reported open-market sales of LifeStance common stock through entities he is associated with. On April 24, Shama LLC sold 31,074 shares and Vitthal LLC sold 31,073 shares at a reported price of $7.05 per share. On April 23, Shama LLC and Vitthal LLC each sold 3,876 shares at a reported price of $7.00 per share.
After these transactions, reported indirect holdings included 1,391,246 shares through Shama LLC, 1,274,448 shares through Vitthal LLC and 36,363 shares held of record by Alpine Glow Capital, plus 57,619 shares held directly. The footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
LFST submitted a Form 144 notice for proposed sales of Common Stock by affiliated holders. The filing lists 438,074.20 (unit shown) and identifies specific transfers originating from private placements dated 06/01/2017 to Vitthal and Shama entities. The filing also reports actual sales by Robert Bessler of 5,101 and 7,752 shares on 04/21/2026 and 04/23/2026, respectively.
LifeStance Health Group, Inc. director Robert Bessler reported open-market sales of company common stock on April 21, 2026 through entities he is associated with. Shama LLC sold 2,550 shares and Vitthal LLC sold 2,551 shares at a weighted average price of $7.01 per share, within a range of $7.00 to $7.02.
After these sales, Shama LLC held 1,426,196 shares and Vitthal LLC held 1,309,397 shares of LifeStance common stock. Separate entries show 36,363 shares held indirectly, described as held by Alpine Glow Capital, and 57,619 shares held directly by Bessler. The reporting person disclaims beneficial ownership of the LLC- and Alpine Glow-held shares except to the extent of his pecuniary interest.
LifeStance Health Group reported a Form 144 notice disclosing the intended sale of 5,101 shares of Common Stock. The filing lists a reported sale on 04/21/2026 of 5,101 shares with proceeds shown as $35,749.48. The filing also records prior private‑placement transfers of 3,876 shares on 06/01/2017 for two trust-to-LLC transfers (Vitthal and Shama).
LifeStance Health Group, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 2, 2026. Stockholders will elect two Class II directors (including CEO David Bourdon and director Robert Bessler) to terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and approve an advisory say‑on‑pay vote.
The record date is April 10, 2026, with 387,827,677 shares of common stock entitled to vote. In 2025, LifeStance reported revenue of $1.42 billion, up 14%, net income of $9.7 million, Adjusted EBITDA of $157.7 million (up 32%), 9.0 million visits and 8,040 clinicians. Executive pay combines base salary, annual bonuses tied mainly to revenue, Adjusted EBITDA and patient satisfaction, plus time‑based and performance‑based RSUs to align leadership with long‑term stockholder value.
LFST reported a Form 144 filing indicating an intended sale of 35,749.48 shares via Fidelity Brokerage Services on 04/21/2026. The excerpt lists two privately placed lots originally acquired on 06/01/2017 and transferred from gift trusts to related LLCs (Vitthal/Shama), showing quantities 2,551 and 2,550.
LifeStance Health Group director and officer Ryan Pardo reported a routine tax-related share withholding tied to vesting equity. On April 1, 2026, 9,376 shares of common stock were withheld at $6.37 per share to cover tax obligations from restricted stock units that vested on March 9, 2026. The filing states this was not an open-market sale. After the withholding, Pardo directly held 1,093,366 shares, and an additional 2,551,520 shares were reported as held indirectly by a trust, with beneficial ownership of those trust shares disclaimed except for his pecuniary interest.
LifeStance Health Group, Inc. officer Ryan McGroarty reported a Form 4 showing 24,255 shares of common stock withheld at $6.45 per share to cover tax obligations when restricted stock units vested on March 24, 2026. These withheld shares were not sold on the open market. After the transaction, McGroarty directly holds 772,235 shares of common stock.
LifeStance Health Group, Inc. reported that company officer Ryan McGroarty had restricted stock units vest on March 17, 2026, and 47,594 shares of common stock were withheld at $6.89 per share to cover tax obligations. The filing states this was not an open-market sale. After the withholding, McGroarty directly holds 796,490 shares of LifeStance common stock.